August 6, 2019 07:13 AM EDTUpdated August 7, 04:20 AM

Neoleukin's quest to shake up the IL-2 space gets a boost via reverse merger with Aquinox

Amber Tong

Months after launching out of the University of Washington, Neoleukin Therapeutics is making a swift leap to the Nasdaq and gaining momentum to push …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neoleukin's quest to shake up the IL-2 space gets a boost via reverse merger with Aquinox

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

GSK defiant against vaccine challenges, will prioritize other growth areas

Small personalized vaccine trial sees progress in late-stage kidney cancer

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Ne­oleuk­in's quest to shake up the IL-2 space gets a boost via re­verse merg­er with Aquinox

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Neoleukin's quest to shake up the IL-2 space gets a boost via reverse merger with Aquinox